Eksempler på bruk av Reconstituted concentrate på Engelsk og deres oversettelse til Norsk
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Appearance of reconstituted concentrate.
Reconstituted concentrate: should be used immediately.
Preparation of the reconstituted concentrate.
Reconstituted concentrate must be further diluted prior to administration.
Therefore, please discard unused reconstituted concentrate immediately.
Both the reconstituted concentrate and the solution for infusion should be visually inspected prior to use.
Other components are also used,with the help of which the reconstituted, concentrated and long-stored juices are made.
Shelf life of reconstituted concentrate: The reconstituted concentrate should be diluted immediately after preparation.
Telavancin dose(mg) 10 mg/kg(or 7.5 mg/kg) x patient body weight(in kg)Volume of reconstituted concentrate(ml) Telavancin dose(mg)/15 mg/ml.
If docetaxel powder, reconstituted concentrate or solution for infusion should come into contact with skin, wash immediately and thoroughly with soap and water.
The solution for infusion is prepared by aseptically adding the appropriate amount of reconstituted concentrate(as shown in the table below) to a 250 mL infusion bag or bottle.
If docetaxel powder, reconstituted concentrate, or solution for infusion should come into contact with mucous membranes, wash immediately and thoroughly with water.
For dilution, gently invert the vial, vial adapter and syringe assembly andwithdraw the required volume of the reconstituted concentrate into the syringe see table below.
Preparation of the reconstituted concentrate VIBATIV 250 mg vial.
The overfills are included to ensure that, after dilution with the entire volume ofthe accompanying solvent vial, the minimum extractable volume of reconstituted concentrate containing 20 mg or 80 mg docetaxel, respectively, may be withdrawn from the vial.
The required volume of the reconstituted concentrate is then added to a recommended compatible infusion solution listed below to obtain a final VFEND solution containing 0.5 to 5 mg/ml of voriconazole.
The overfills are included to ensure that, after dilution with the entire volume ofthe accompanying solvent vial, the minimum extractable volume of reconstituted concentrate containing 20 mg or 80 mg docetaxel, respectively, may be withdrawn from the vial.
For administration, the required volume of the reconstituted concentrate is added to a recommended compatible infusion solution(detailed in the table below) to obtain a final voriconazole solution containing 0.5-5 mg/ml.
For doses of 150 to 800 mg, the appropriate volume of reconstituted concentrate must be further diluted in 100 to 250 ml prior to infusion.
The volume of reconstituted concentrate corresponding to the calculated individual dose, should be further diluted with either sodium chloride 9 mg/ml(0.9%) solution for injection or 50 mg/ml(5%) glucose solution for infusion, to a final concentration of between 25 and 50 microgram per ml in the solution for infusion, for example.
The required volume of the reconstituted concentrate is then added to a recommended compatible.